Zenas Biopharma outlines obexelimab regulatory filings, pipeline milestones in corporate presentation

• Zenas Biopharma highlighted FDA acceptance of its BLA for obexelimab in IgG4-related disease, with a PDUFA date of May 27, 2027.
• Phase 3 INDIGO met its primary endpoint, cutting flare risk 56% versus placebo; 73% of treated patients were flare-free.
• Key secondary endpoints favored obexelimab, including higher complete remission at week 52: 37.1% versus 19.6% on placebo.
• European regulatory filing for IgG4-RD is planned in 2H 2026 via an MAA submission to the EMA.
• Pipeline priorities include Phase 3 orelabrutinib studies in progressive MS, with additional clinical readouts expected in late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.